Gapping down
Select metals/mining stocks trading lower on weakness in precious metals post-Fed: CDE -6.0%, GFI -5.6%, EGO -5.3%, HMY -5.0%, AU -4.8%, AG -4.5%, GOLD -4.3%, SLV -4.3%, FSM -4.1%, SSRI -4.1%, HL -3.7%, SLW -3.6%, RIO -3.5%, NEM -3.2%, FCX -3.1%, AEM -3.0%, GG -3.1%, ABX -2.9%, AUY -2.9%, PAAS -2.7%, SAND -3.1%, BTG -2.7%, TSU -2.6%, TECK -2.6%.Other news: SGY -25% (filed voluntary petitions under chapter 11 to pursue a pre-packaged plan of reorganization ), FOLD -12.0% (announces an offering of $225 mln convertible senior notes due 2023 in a private placement), KCAP -8.0% (reduces quarterly distribution to $0.12/share from $0.15/share), MPEL -5.3% (confirms launch of underwritten, secondary public offering of its American depositary shares by Crown Resorts), FANG -4.0% (Diamondback Energy to acquire Brigham Resources and Brigham Resources Midstream for $2.43 bln (immediately accretive), consisting of $1.62 bln in cash and 7.69 mln FANG shares; announces 10.5 mln share offering and notes offering; raises FY17 production 25% ), DNR -3.5% (still checking), YHOO -3.4% (confirms it has identified data security issues concerning certain Yahoo user accounts; has taken steps to secure user accounts and is working closely with law enforcement), GPOR -3.1% ( to acquire approx. 46,400 net surface acres in the core of the SCOOP for a total purchase price of $1.85 bln from Quantum Energy Partners; commences underwritten public offering of 29,000,000 shares of its common stock and launches proposed $600 million offering of senior notes due 2025 ), CLF -2.7% (names new CFO and new COO).
- The previously announced agreement provided the option for Roche (RHHBY) to terminate the agreement for any reason with sixty days' prior notice. Upon termination, other than retaining certain non-exclusive rights with respect to using products already purchased from Pacific Biosciences under the agreement, Roche will have no rights to SMRT technology, and Pacific Biosciences will be free to commercialize products based on the Sequel sequencing platform into the clinical research and sequencing market, directly or with other distribution partners.
- Pacific Biosciences continues to see strength in its business. The company's product and service revenue for 2016 is on pace to grow between 55% and 65% over 2015. The co is targeting to grow product and service revenue by another 40% to 60% in 2017.
- Management will host a conference call to discuss the announcement today at 12:00pm Eastern Time / 9:00am Pacific Time.
Gapping up
In reaction to strong earnings/guidance: PIR +26.5%, ARWR +9.5%, SAFM +5.3%, LLY +3.7% (reaffirms FY16 expectations, guides FY17, reaffirms financial expectations through the remainder of the decade).
Other news: CBIO +48.7% (Catalyst Biosciences entered into an agreement with Pfizer subsidiary Wyeth for the exclusive license to Wyeth's rights applying to CB813a & CB813d; co to make a $17.5 mln cash payment to Wyeth upon the achievement of milestones), BOSC +30.2% (receives $1.6 mln order for electronic components from an Indian electronics manufacturing co in the defense/aerospace industry; order is for delivery in 2017 and 2018), ACUR +11.0% (FDA has provided it with advice on the continued development of LTX-04; co intends to advance new formulations of LTX-04 tablets to a second pharmacokinetic study which is expected to start in late 1Q17), ONVO +5.7% (continued strength), NMM +4.9% (still checking for anything specific), MDLZ +4.9% (moved higher on rumor that Kraft Heinz (KHC) could be interested in acquiring co; subsequent reports have denied the rumor), WTW +1.9% (announces new subscription plan that includes a new Apple Watch Series 2 with the purchase of a Weight Watchers OnlinePlus membership), PPC +1.2% (up with SAFM).
Analyst actions: XLNX +1.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley), COF +1.2% (upgraded to Neutral from Underperform at BofA/Merrill), MA +1.1% (upgraded to Buy from Neutral at BofA/Merrill).